These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 27003434)

  • 1. Acute liver damage following intravenous glucocorticoid treatment for Graves' ophthalmopathy.
    Moleti M; Giuffrida G; Sturniolo G; Squadrito G; Campennì A; Morelli S; Puxeddu E; Sisti E; Trimarchi F; Vermiglio F; Marinò M
    Endocrine; 2016 Oct; 54(1):259-268. PubMed ID: 27003434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age and Dose Are Major Risk Factors for Liver Damage Associated with Intravenous Glucocorticoid Pulse Therapy for Graves' Orbitopathy.
    Sisti E; Coco B; Menconi F; Leo M; Rocchi R; Latrofa F; Profilo MA; Mazzi B; Vitti P; Marcocci C; Brunetto M; Marinò M
    Thyroid; 2015 Jul; 25(7):846-50. PubMed ID: 26090805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statins may increase the risk of liver dysfunction in patients treated with steroids for active graves' orbitopathy.
    Covelli D; Vannucchi G; Campi I; Currò N; D'Ambrosio R; Maggioni M; Gianelli U; Beck-Peccoz P; Salvi M
    J Clin Endocrinol Metab; 2015 May; 100(5):1731-7. PubMed ID: 25751109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of Graves' orbitopathy treatment with intravenous glucocorticoids on adrenal function.
    Ambroziak U; Bluszcz G; Bednarczuk T; Miśkiewicz P
    Endokrynol Pol; 2017; 68(4):430-433. PubMed ID: 28604944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statins are not a risk factor for liver damage associated with intravenous glucocorticoid pulse therapy for Graves' orbitopathy.
    Sabini E; Sisti E; Coco B; Leo M; Ionni I; Menconi F; Profilo MA; Mazzi B; Rocchi R; Latrofa F; Vitti P; Brunetto M; Marcocci C; Marinò M
    J Endocrinol Invest; 2016 Nov; 39(11):1323-1327. PubMed ID: 27465669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous glucocorticoid therapy for Graves' ophthalmopathy and acute liver damage: an epidemiological study.
    Sisti E; Coco B; Menconi F; Leo M; Rocchi R; Latrofa F; Profilo MA; Mazzi B; Albano E; Vitti P; Marcocci C; Brunetto M; Marinò M
    Eur J Endocrinol; 2015 Mar; 172(3):269-76. PubMed ID: 25661744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fatal and non-fatal adverse events of glucocorticoid therapy for Graves' orbitopathy: a questionnaire survey among members of the European Thyroid Association.
    Marcocci C; Watt T; Altea MA; Rasmussen AK; Feldt-Rasmussen U; Orgiazzi J; Bartalena L;
    Eur J Endocrinol; 2012 Feb; 166(2):247-53. PubMed ID: 22058081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The therapeutic outcome to intravenous steroid therapy for active Graves' orbitopathy is influenced by the time of response but not polymorphisms of the glucocorticoid receptor.
    Vannucchi G; Covelli D; Campi I; Origo D; Currò N; Cirello V; Dazzi D; Beck-Peccoz P; Salvi M
    Eur J Endocrinol; 2014 Jan; 170(1):55-61. PubMed ID: 24128430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determinants of liver damage associated with intravenous methylprednisolone pulse therapy in Graves' ophthalmopathy.
    Le Moli R; Baldeschi L; Saeed P; Regensburg N; Mourits MP; Wiersinga WM
    Thyroid; 2007 Apr; 17(4):357-62. PubMed ID: 17465867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcome of Graves' orbitopathy following high-dose intravenous glucocorticoids and orbital radiotherapy.
    Sisti E; Menconi F; Leo M; Profilo MA; Mautone T; Mazzi B; Rocchi R; Latrofa F; Nardi M; Vitti P; Marcocci C; Marinò M
    J Endocrinol Invest; 2015 Jun; 38(6):661-8. PubMed ID: 25596664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-analysis of methylprednisolone pulse therapy for Graves' ophthalmopathy.
    Gao G; Dai J; Qian Y; Ma F
    Clin Exp Ophthalmol; 2014 Nov; 42(8):769-77. PubMed ID: 24617953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver injury after methylprednisolone pulses: A disputable cause of hepatotoxicity. A case series and literature review.
    Zoubek ME; Pinazo-Bandera J; Ortega-Alonso A; Hernández N; Crespo J; Contreras F; Medina-Cáliz I; Sanabria-Cabrera J; Sanjuan-Jiménez R; González-Jiménez A; García-Cortés M; Lucena MI; Andrade RJ; Robles-Díaz M
    United European Gastroenterol J; 2019 Jul; 7(6):825-837. PubMed ID: 31316787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between longitudinal behaviour of some markers of eye autoimmunity and changes in ocular findings in patients with Graves' ophthalmopathy receiving corticosteroid therapy.
    De Bellis A; Bizzarro A; Conte M; Coronella C; Solimeno S; Perrino S; Sansone D; Guaglione M; Wall JR; Bellastella A
    Clin Endocrinol (Oxf); 2003 Sep; 59(3):388-95. PubMed ID: 12919164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of intravenous methylprednisolone therapy vs. oral methylprednisolone therapy in patients with Graves' ophthalmopathy.
    Aktaran S; Akarsu E; Erbağci I; Araz M; Okumuş S; Kartal M
    Int J Clin Pract; 2007 Jan; 61(1):45-51. PubMed ID: 16889639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methylprednisolone-induced liver injury: a diagnostic challenge.
    Melamud B; Lurie Y; Goldin E; Levi I; Esayag Y
    Isr Med Assoc J; 2014 Mar; 16(3):180-1. PubMed ID: 24761710
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study.
    Marcocci C; Bartalena L; Tanda ML; Manetti L; Dell'Unto E; Rocchi R; Barbesino G; Mazzi B; Bartolomei MP; Lepri P; Cartei F; Nardi M; Pinchera A
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3562-7. PubMed ID: 11502779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves' orbitopathy?
    Bartalena L; Veronesi G; Krassas GE; Wiersinga WM; Marcocci C; Marinò M; Salvi M; Daumerie C; Bournaud C; Stahl M; Sassi L; Azzolini C; Boboridis KG; Mourits MP; Soeters MR; Baldeschi L; Nardi M; Currò N; Boschi A; Bernard M; von Arx G; Perros P; Kahaly GJ;
    J Endocrinol Invest; 2017 May; 40(5):547-553. PubMed ID: 28176220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum concentrations of HGF and IL-8 in patients with active Graves' orbitopathy before and after methylprednisolone therapy.
    Nowak M; Siemińska L; Karpe J; Marek B; Kos-Kudła B; Kajdaniuk D
    J Endocrinol Invest; 2016 Jan; 39(1):63-72. PubMed ID: 26062519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methylprednisolone and hepatotoxicity in Graves' ophthalmopathy.
    Wichary H; Gasińska T
    Thyroid; 2012 Jan; 22(1):64-9. PubMed ID: 22029719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Graves' ophthalmopathy with high-dose intravenous methylprednisolone: a comparison of two dosing regimens.
    Sánchez-Ortiga R; Moreno-Pérez O; González Sánchez V; Arias Mendoza N; Mauri Dot M; Alfayate Guerra R; López Macia A; Picó Alfonso A
    Endocrinol Nutr; 2009 Mar; 56(3):118-22. PubMed ID: 19627724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.